基线PSMA PET/CT对同步转移性激素敏感性前列腺癌生存的预后价值
本研究纳入204例同步转移性激素敏感性前列腺癌患者,均接受PSMA PET/CT分期并由多学科团队前瞻性分为低/高瘤负荷。结果显示PSMA肿瘤总体积是总生存期的独立预测因子,联合体能状态模型的C指数为0.71。探索性分析提出PSMA-TV≥150 mL或存在内脏转移可作为高瘤负荷新标准。
要点
- PSMA-TV每翻一倍,总生存期风险增加39%,是独立于体能状态和治疗的稳健预后因子。
- PSMA-TV联合WHO体能状态的模型C指数0.71,优于单纯二分类高/低瘤负荷分层。
- 日常报告中可尝试量化PSMA-TV,但新阈值需多中心验证后方可临床推广。
核心结论
- MDT分层对同步转移性激素敏感性前列腺癌患者足够有效,但纳入PSMA-TV可进一步改善风险评估。
- 作者建议将PSMA-TV作为连续变量纳入模型指导治疗决策,而非采用二分类高/低瘤负荷。
- 新提出的高瘤负荷标准为PSMA-TV≥150 mL或存在任何内脏转移,其风险比与MDT分层相近。
研究设计与样本
- 回顾性分析2017至2023年间204例同步转移性激素敏感性前列腺癌患者,均以PSMA PET/CT分期。
- MDT前瞻性共识将患者分为低瘤负荷75例和高瘤负荷129例。
- 回顾性收集PSMA-TV、TL-PSMA、DmaxVox、SUVmax、SUVmean及转移状态,并采集年龄、WHO-PS、Gleason评分和实验室指标。
- 采用Cox回归识别总生存期预测因子,模型性能以Harrell C指数评估并经bootstrap内部验证。
关键影像表现/征象
- MDT判定的LVD与HVD间PSMA-TV中位数差异显著,分别为60 mL与483 mL。
- LVD与HVD组总生存期中位数分别为69个月与41个月,差异显著。
诊断标准与关键数值
- PSMA-TV预测总生存期风险比为1.39(每翻一倍,p<0.001)。
- WHO-PS预测总生存期风险比为1.69(每增加一级,p<0.001)。
- PSMA-TV联合WHO-PS模型经bootstrap后C指数为0.71(95%CI 0.66-0.77)。
- 探索性事后分析中PSMA-TV≥150 mL或存在内脏转移作为高瘤负荷标准,风险比为3.01,MDT分层风险比为2.68。
临床应用与阅片要点
- PSMA PET/CT定量肿瘤负荷评估可改善转移性激素敏感性前列腺癌的预后分层,支持更个体化的治疗选择。
- 在报告中量化PSMA-TV可作为补充信息,帮助临床评估预后并讨论治疗方案。
- 需注意目前新阈值尚未经多中心验证,暂不宜作为独立决策依据。
局限性
- 本研究为回顾性分析,MDT分层虽为前瞻性但影像解读存在主观性。
- 作者明确指出多中心验证是临床实施前必需的步骤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Traditional metastatic burden classifications in metastatic hormone-sensitive prostate cancer (mHSPC) rely on conventional imaging using CHAARTED criteria. As PSMA PET/CT is increasingly used for staging, revised definitions of low-volume (LVD) and high-volume disease (HVD) are needed to guide treatment decisions.
MATERIALS AND METHODS: This study included 204 patients with synchronous mHSPC staged with PSMA PET/CT between 2017 and 2023. As part of standard clinical practice, patients were prospectively classified as LVD or HVD by a multidisciplinary team (MDT) consensus. Retrospective analysis collected PSMA-total tumour volume (PSMA-TV), total lesion uptake (TL-PSMA), maximum distance between voxels (DmaxVox), SUVmax, SUVmean and metastatic status. Additionally, age, WHO performance status (WHO-PS), Gleason score and laboratory values were retrieved. Cox regression identified predictors of overall survival (OS). Model performance was assessed using Harrell's C-index with internal validation via bootstrapping.
RESULTS: By MDT consensus, 75 patients (37%) had LVD and 129 patients (63%) had HVD, differing significantly in PSMA-TV (median: 60 vs. 483 mL) and OS (median: 69 vs. 41 months). PSMA-TV was a robust predictor of OS (HR = 1.39 per doubling, p < 0.001), independent of WHO-PS (HR = 1.69 per score increase, p < 0.001) and treatment. A model combining PSMA-TV and WHO-PS achieved a C-index of 0.71 (95% CI 0.66-0.77) after bootstrapping. In an exploratory post hoc analysis, the optimal threshold for PSMA-TV-based high-volume disease was PSMA-TV ≥ 150 mL or any visceral metastasis, which performed similarly to MDT-based classification (HR = 3.01 vs. HR = 2.68).
CONCLUSION: While MDT-based stratification of mHSPC patients was adequate, incorporating PSMA-TV can further improve risk assessment. Instead of dichotomising, we propose using a model with PSMA-TV as a continuous variable to guide treatment decisions. Multicentre validation is needed before clinical implementation.
KEY POINTS: Question As PSMA PET/CT replaces conventional imaging for staging metastatic hormone-sensitive prostate cancer, revised PSMA PET/CT-based metastatic burden classifications are needed to guide treatment decisions. Findings PSMA-total tumour volume (PSMA-TV) was a robust predictor of overall survival, and a model combining PSMA-TV with performance status achieved a C-index of 0.71 after bootstrapping. Clinical relevance Quantitative tumour burden assessment with PSMA PET/CT can improve prognostic stratification in metastatic hormone-sensitive prostate cancer, supporting more individualised treatment selection.
引用
- Kleiburg, Heijmen, Witteveen, et al. Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease. Eur Radiol. 2026. PMID: 42749930. doi:10.1007/s00330-026-12875-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。